LY3462817 (SC) for Healthy Subjects (HS)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Altasciences Clinical Los Angeles, Inc, Cypress, CA
Healthy Subjects (HS)
LY3462817 (SC) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3462817 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3462817 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 12 weeks.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Healthy Subjects (HS)

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Predose on Day 1 through Day 85

Baseline through Week 12
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Day 85
PK: Maximum Concentration (Cmax) of LY3462817
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3462817

Trial Safety

Safety Progress

1 of 3

Other trials for Healthy Subjects (HS)

Trial Design

4 Treatment Groups

LY3462817 - SC
1 of 4
LY3462817 - IV
1 of 4
Placebo - SC
1 of 4
Placebo - IV
1 of 4
Experimental Treatment
Non-Treatment Group

32 Total Participants · 4 Treatment Groups

Primary Treatment: LY3462817 (SC) · Has Placebo Group · Phase 1

LY3462817 - SC
Drug
Experimental Group · 1 Intervention: LY3462817 (SC) · Intervention Types: Drug
LY3462817 - IV
Drug
Experimental Group · 1 Intervention: LY3462817 (IV) · Intervention Types: Drug
Placebo - SC
Drug
PlaceboComparator Group · 1 Intervention: Placebo (SC) · Intervention Types: Drug
Placebo - IV
Drug
PlaceboComparator Group · 1 Intervention: Placebo (IV) · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: predose on day 1 through day 85
Closest Location: Altasciences Clinical Los Angeles, Inc · Cypress, CA
Photo of california 1Photo of california 2Photo of california 3
2022First Recorded Clinical Trial
6 TrialsResearching Healthy Subjects (HS)
2 CompletedClinical Trials

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,427 Previous Clinical Trials
3,102,411 Total Patients Enrolled
313 Trials studying Healthy Subjects (HS)
15,791 Patients Enrolled for Healthy Subjects (HS)
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,231 Previous Clinical Trials
364,026 Total Patients Enrolled
272 Trials studying Healthy Subjects (HS)
13,339 Patients Enrolled for Healthy Subjects (HS)

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have no medical conditions that would preclude you from participating in the study.
You are a non-Japanese participant.
You are of childbearing potential.
You have the necessary medical and psychological conditions for the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.